ArticleJournal of the American Heart Association2025
Inhibition of NPC Intracellular Cholesterol Transporter 1 Dually Regulates Aldosterone Secretion Via the Steroidogenic Acute Regulatory-Related Lipid Transfer Domain-3-Voltage-Dependent Anion Channel 1 Axis and Inositol 1,4,5-Trisphosphate Receptor Type 3-Calcium Signaling.
Jun Chen, Miaoyun Chen, Jinbo Hu, Zhipeng Wu, Hongji Li, Wuchao Li, Furong He, Chuan Peng, Yong Xu, Wei Huang and 4 more
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Jun ChenDepartment of Endocrinology, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases the First Affiliated Hospital of Chongqing Medical University Chongqing China.
Miaoyun ChenDepartment of Endocrinology, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases the First Affiliated Hospital of Chongqing Medical University Chongqing China.
Jinbo HuDepartment of Endocrinology, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases the First Affiliated Hospital of Chongqing Medical University Chongqing China.ORCID 0000-0003-2925-0583
Zhipeng WuDepartment of Endocrinology, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases the First Affiliated Hospital of Chongqing Medical University Chongqing China.
Hongji LiDepartment of Endocrinology, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases the First Affiliated Hospital of Chongqing Medical University Chongqing China.
Wuchao LiDepartment of Endocrinology, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases the First Affiliated Hospital of Chongqing Medical University Chongqing China.
Furong HeDepartment of Endocrinology, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases the First Affiliated Hospital of Chongqing Medical University Chongqing China.
Chuan PengDepartment of Endocrinology, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases the First Affiliated Hospital of Chongqing Medical University Chongqing China.ORCID 0009-0009-5495-3732
Yong XuDepartment of Endocrinology and Metabolism, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases the Affiliated Hospital of Southwest Medical University Luzhou Sichuan China.
Wei HuangDepartment of Endocrinology and Metabolism, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases the Affiliated Hospital of Southwest Medical University Luzhou Sichuan China.
Rufei GaoSchool of Public Health and Management Chongqing Medical University Chongqing China.ORCID 0000-0003-1409-4995
Qifu LiDepartment of Endocrinology, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases the First Affiliated Hospital of Chongqing Medical University Chongqing China.ORCID 0000-0001-7249-6445
Linqiang MaDepartment of Endocrinology, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases the First Affiliated Hospital of Chongqing Medical University Chongqing China.
Shumin YangDepartment of Endocrinology, Sichuan-Chongqing Joint Key Laboratory of Metabolic Vascular Diseases, Chongqing Key Laboratory of Translational Medicine in Major Metabolic Diseases the First Affiliated Hospital of Chongqing Medical University Chongqing China.ORCID 0000-0002-0238-4779
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundAldosterone-producing adenomas, a prevalent cause of endocrine hypertension, arise from uncontrolled aldosterone production. NPC1 (NPC intracellular cholesterol transporter 1) is a cholesterol transporter located on the lysosomal limiting membrane. Although cholesterol serves as the primary precursor for aldosterone synthesis, the mechanism governing its supply and metabolism within aldosterone-producing adenomas remains unclear.
methodsIn this study, we used quantitative proteomics and observed that NPC1 was significantly downregulated in aldosterone-producing adenoma tissues.
resultsLiquid chromatography/tandem mass spectrometry analysis found that inhibition of NPC1 increased aldosterone secretion in H295R cells. Mechanistically, NPC1 deficiency promoted aldosterone production through 2 pathways: (1) immunofluorescence and coimmunoprecipitation experiments confirmed that NPC1 deficiency enhanced lysosome-mitochondria interaction via STARD3-VDAC1 (steroidogenic acute regulatory-related lipid transfer domain-3-voltage-dependent anion channel 1), leading to mitochondrial cholesterol overload; and (2) Western Blot and calcium measurement showed that NPC1 deficiency activated of cytoplasmic calcium signaling through IP3R3 (inositol 1,4,5-trisphosphate receptor type 3)-mediated endoplasmic reticulum calcium release, resulting in upregulated expression of aldosterone synthase.
conclusionsOur findings demonstrate that NPC1 downregulation represents a novel mechanism driving elevated aldosterone production, linking lysosomal-mitochondria cholesterol transport to aldosterone high production. These results suggest that NPC1 may offer a new understanding for aldosterone overproduction mechanism of aldosterone-producing adenomas.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Inhibition of NPC Intracellular Cholesterol Transporter 1 Dually Regulates Aldosterone Secretion Via the Steroidogenic Acute Regulatory-Related Lipid Transfer Domain-3-Voltage-Dependent Anion Channel 1 Axis and Inositol 1,4,5-Trisphosphate Receptor Type 3-Calcium Signaling. · full record | OpenQuestion